What insurance policy changes affect HCPCS J9201?

There are 10 tracked policy changes affecting HCPCS J9201, including updates from UnitedHealthcare, Aetna, Florida Blue. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9201?

Payers that have issued tracked updates for HCPCS J9201 include: UnitedHealthcare, Aetna, Florida Blue, Highmark.

How do I get notified when HCPCS J9201 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9201. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9201?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg: Insurance Policy Changes

J9201 Insurance Policy Changes

HCPCS J9201 is officially defined as "Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg." HCPCS J9201 is referenced in 10 tracked payer policy changes from UnitedHealthcare, Aetna, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9201 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Aetna·Effective Feb 24, 2026

Aetna has updated its coverage policy for Irinotecan Liposome Injection (Onivyde) effective immediately, establishing specific medical necessity criteria for ampullary adenocarcinoma and pancreatic adenocarcinoma treatments. The policy defines approved indications including first-line NALIRIFOX regimens, subsequent therapy scenarios, and dosing requirements, while designating all other uses as experimental/investigational. Billing teams must verify patient diagnoses, treatment lines, prior therapy history, and performance status documentation before processing claims for HCPCS code J9205.

J9201 Insurance Policy Changes

Changes to injectable oncology drug coverage are coming

Ramucirumab (Cyramza) (CPB 0883, reviewed 2026-06-03)

Medicare Part B Step Therapy May Updates

Prior Authorization Changes to Oncology-related Codes

Sacituzumab Govitecan-hziy (Trodelvy) (CPB 0971, reviewed 2026-04-24)

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Gemcitabine (CPB 0958, reviewed 2026-07-17)

Necitumumab (Portrazza) (CPB 0898, reviewed 2026-07-02)

Penpulimab-kcqx (CPB 1080, reviewed 2026-04-15)

Cabazitaxel (Jevtana) (CPB 0806, reviewed 2026-03-12)